2018 US Medicinal Products

Financial Strength Rankings using Artificial Intelligence

Top rated12 of 48
Best rating2,152 %
Worst rating-2,339 %
New companies5
Negative Economic Capital Ratio21 of 48

Navidea Biopharmaceuticals Inc. climbed 32 positions from 33 to 1 due it’s excellent Net Income. FITLIFE BRANDS INC. lost 24 positions from 14 to 38 due it’s bad Assets. MARIMED INC. entered the 2018 ranking at rank 15, making it the best newcomer.

Revenues28.2 B
Assets45.6 B
Expenses27.1 B
Stockholders Equity18.5 B
Unprofitable companies27 of 48

3. NEOGEN CORP

236.04%

6. INNOSPEC INC.

202.46%

8. FMC CORP

181.51%

9. HESKA CORP

175.49%

11. BALCHEM CORP

160.99%

12. MYRIAD GENETICS INC

113.92%

13. IMMUCELL CORP DE

112.52%

14. Ingevity Corp

110.37%

15. MARIMED INC.

97.68%

16. MANNATECH INC

80.96%

18. CYANOTECH CORP

63.93%

19. Chemours Co

62.04%

20. OLIN Corp

59.99%

21. Ecovyst Inc.

59.69%

24. OCI Partners LP

45.81%

25. BIOMERICA INC

44.88%

26. KMG CHEMICALS INC

41.35%

27. W R GRACE & CO

10.08%

31. CAT9 Group Inc.

-231.74%

33. GL Brands Inc.

-389.19%

34. IMMUNOMEDICS INC

-405.96%

36. VOLITIONRX LTD

-506.76%

38. FITLIFE BRANDS INC.

-602.99%

40. NUTRA PHARMA CORP

-720.85%

42. ARCA biopharma Inc.

-881.80%

43. Target Group Inc.

-906.12%

44. Oncocyte Corp

-927.00%

45. TAURIGA SCIENCES INC.

-966.29%

United States Ratings

German Insurance Ratings